Frauenaerztliche Gemeinschaftspraxis Casparistrasse
- Address
- Casparistrasse 5/6, 38100 Braunschweig, Germany
Frauenaerztliche Gemeinschaftspraxis Casparistrasse - Early Breast Cancer Research Center
This specialized gynecological practice is actively engaged in cutting-edge clinical research focused on early breast cancer treatment optimization. The center participates in pivotal trials evaluating personalized, biomarker-driven therapeutic approaches that aim to improve patient outcomes while potentially reducing treatment burden through precision medicine strategies.
- HER2-positive early breast cancer: Novel antibody-drug conjugates versus standard neoadjuvant combination therapies
- Hormone receptor-positive, HER2-negative breast cancer: CDK4/6 inhibitors combined with endocrine therapy as alternatives to chemotherapy
- Dynamic marker-adjusted personalized therapy (ADAPT) protocols for risk-stratified treatment selection
The practice's research portfolio emphasizes pathologic complete response assessment and long-term survival outcomes, including invasive disease-free survival and distant disease-free survival endpoints. Their participation in adaptive trial designs reflects a commitment to identifying patients who may benefit from targeted therapies such as trastuzumab-deruxtecan and ribociclib, potentially sparing appropriate candidates from conventional chemotherapy regimens while maintaining excellent oncologic outcomes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Frauenaerztliche Gemeinschaftspraxis Casparistrasse
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Adjuvant Dynamic Marker-Adjusted Personalized Therapy: Ribociclib Plus Endocrine Therapy Versus Chemotherapy in HR+/HER2- Early Breast Cancer | WSG Westdeutsche Studiengruppe GmbH | Phase III | Not Recruiting | Jul 2019 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ribociclib | 1 | Unknown | 2019-07-02 | 2019-07-02 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.